Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant monoclonal antibody to integrin alpha 4 beta 7. Etrolizumab is a humanized monoclonal antibody designed for the treatment of inflammatory bowel disease.
Target
Integrin alpha 4 beta 7
Type
IgG1 - kappa
Immunogen
The details of the immunogen for this antibody are not available.
Species Reactivity
Human
Expression Host
CHO
Applications
Suitable for use in IF, IP, Neut, FuncS, ELISA, FC, ICC and most other immunological methods.
CAS
1044758-60-2
Specific Activity
Tested positive against native human antigen.
Protein Construction
Immunoglobulin G1, anti-(human integrin alpha-4/beta-7 (Peyer patches-specific homing receptor LPAM-1) and human integrin alpha-E/beta-7 (HML-1 antigen)); humanized rat monoclonal rhuMAb Beta7 des-447-lysine(CH3107K)-γ1 heavy chain (220-214")-disulfide with humanized rat monoclonal rhuMAb Beta7 kappa1 light chain, dimer (226-226"":229-229"")-bisdisulfide
Predicted N terminal
H chain: EVQLVES; L chain: DIQMTQS
Molecular Weight
144100
Purity
>95.0% as determined by analysis by RP-HPLC.
Size
1mg
Storage
At -20°C for one year.
BACKGROUND
Antigen Description
Integrin alpha 4 beta 7, also known as, the lymphocyte Peyer"s patch adhesion molecule (LPAM1) is a member of the integrin family of cell surface receptors. It is expressed primarily on mucosal lymphocytes, but is also present on NK cells and eosinophils. The alpha 4 beta 7 heterodimer mediates the binding of lymphocytes to its ligand, mucosal vascular addressin (MAdCAM1) on the high endothelial venules, thereby directing the homing of lymphocytes into Peyer"s patches and intestinal lamina propria.
Function
fibronectin binding; protein binding; receptor activity;